EP Patent

EP4076402A1 — Dosage form comprising amorphous solid solution of empagliflozin with polymer

Assigned to KRKA dd · Expires 2022-10-26 · 4y expired

What this patent protects

The invention provides solid pharmaceutical dosage forms and methods for making the same, wherein the pharmaceutical dosage forms comprise Empagliflozin in the form of an amorphous solid solution with at least one polymer. The pharmaceutical dosage forms according to the inventio…

USPTO Abstract

The invention provides solid pharmaceutical dosage forms and methods for making the same, wherein the pharmaceutical dosage forms comprise Empagliflozin in the form of an amorphous solid solution with at least one polymer. The pharmaceutical dosage forms according to the invention exhibit excellent stability especially in terms of physical stabilization of amorphous form of Empagliflozin.

Drugs covered by this patent

Patent Metadata

Patent number
EP4076402A1
Jurisdiction
EP
Classification
—
Expires
2022-10-26
Drug substance claim
No
Drug product claim
No
Assignee
KRKA dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.